HS
OVID icon

HighVista Strategies’s Ovid Therapeutics OVID Stock Holding History

HighVista Strategies’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-40,920
Closed -$164K – 134
2021
Q1 		$164K Hold
40,920
– – 0.12% 81
2020
Q4 		$95K Buy
+40,920
New +$191K 0.06% 90

Other funds holding OVID

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
GC
Globeflex Capital San Diego, California $661M AUM 50.59% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

HighVista Strategies's OVID Position: Q2 2021 in Review

HighVista Strategies sold out of Ovid Therapeutics (OVID) in Q2 2021, closing a stake of 40,920 shares — an estimated $164K sold.

HighVista Strategies first reported a position in OVID in Q4 2020 and held it in 2 quarters. The position peaked at $164K in Q1 2021. 80 funds tracked by Wall St. Rank hold OVID as of Q2 2021.

  • HighVista Strategies reported no remaining Ovid Therapeutics position as of Q2 2021 after selling out during the quarter.
  • HighVista Strategies sold 40,920 Ovid Therapeutics shares in Q2 2021, an estimated $164K.
  • HighVista Strategies first reported a position in Ovid Therapeutics in Q4 2020 and held it in 2 quarters.
  • HighVista Strategies's Ovid Therapeutics position peaked at $164K in Q1 2021.
  • 80 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q2 2021.

Based on HighVista Strategies's 13F filing for Q2 2021, filed 16 Aug 2021.